Endometriosis, a painful condition affecting 1 in 10 women, often takes years to diagnose. New AI-driven tests developed outside the U.S. show promise in detecting the disease earlier, potentially reducing diagnostic delays.
The development of new diagnostic tools, particularly those leveraging AI and advanced biological analysis, could significantly reduce the prolonged suffering and diagnostic delays experienced by millions of women with endometriosis, improving their quality of life and enabling timely treatment.
Endometriosis, a chronic inflammatory disease affecting one in ten women worldwide, often eludes diagnosis for years due to normalized period pain and overlapping symptoms. Zoë Armstrong, a 31-year-old, shared her decade-long struggle before finally receiving a diagnosis. The condition can cause debilitating pain, fatigue, bloating, and infertility.
New diagnostic tests are emerging internationally, offering hope for earlier detection. EndoSure, a test measuring electrical signals in the gut, and Endotest, which analyzes saliva for microRNAs, are available in some countries. The UK's National Health Service is considering using these tests to expedite diagnosis. EndoSure is pursuing FDA approval in the U.S., while Endotest is being made available through certified laboratories.
U.S. medical experts acknowledge these tests could be valuable additions to the diagnostic process but emphasize they will not replace existing methods and may not fully address the issue of normalizing period pain. Treatment options for endometriosis include pain relievers, hormone therapies, and surgical interventions.